Background
Methods
Eligibility criteria
Search strategy
Study selection, data extraction and quality assessment
Statistical Analysis
Results
Study description
Study | Total Sample Size(n) | Adverse effects¥
| Mean Age | % Male | Trial Duration with 1 mg BID dose(Weeks) | Size of Trial group | Size of Control Group | Cochrane risk of bias assessment§
| ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P | Q | R | S | T | U | Overall score | ||||||||
Gonzales et al (2006)
32
| 696 | A, B, C | 42.55 | 52.05 | 12 | 352 | 344 | 1 | 1 | 1 | 1 | 1 | 1 | 6/6 |
Jorenby et al(2006)
29
| 685 | A, B, C | 43.45 | 56.65 | 12 | 344 | 341 | 1 | 1 | 1 | 1 | 1 | 0 | 5/6 |
Oncken et al(2006)
27
| 259 | A, B, C | 41.1 | 50.2 | 12 | 130 | 129 | 1 | 1 | 1 | 1 | 0 | 0 | 4/6 |
Nides et al(2006)
25
| 248 | A, B | 41.7 | 51.2 | 6 | 125 | 123 | 1 | 1 | 0 | 1 | 1 | 0 | 4/6 |
Nakamura et al(2007)
30
| 310 | A, B | 40 | 77.6 | 12 | 156 | 154 | 1 | 1 | 1 | 1 | 1 | 1 | 6/6 |
Tsai et al(2007)
28
| 250 | A, B | 40.3 | 88.8 | 12 | 126 | 124 | 1 | 1 | 0 | 1 | 1 | 0 | 4/6 |
Williams et al(2007)
26
| 377 | A, B, C | 47.7 | 48.6 | 52 | 251 | 126 | 1 | 1 | 0 | 1 | 1 | 0 | 4/6 |
Niaura et al(2008)
34
| 312 | A | 41.8 | 51.9 | 12 | 157 | 155 | 1 | 1 | 1 | 1 | 1 | 0 | 5/6 |
Wang et al(2009)
33
| 333 | A | 38.7 | 96.7 | 12 | 165 | 168 | 1 | 1 | 0 | 1 | 1 | 0 | 4/6 |
Rigotti et al(2010)
31
| 714 | A, B | 56.45 | 78.7 | 12 | 355 | 359 | 1 | 1 | 0 | 1 | 1 | 1 | 5/6 |
Fagerstrom et al(2010)
8
| 431 | A | 43.9 | 89.3 | 12 | 213 | 218 | 1 | 1 | 1 | 1 | 1 | 1 | 6/6 |
Tashkin et al(2010)
24
| 499 | A, C | 57.2 | 62.3 | 12 | 248 | 251 | 1 | 1 | 0 | 1 | 1 | 0 | 4/6 |